Matthew Stannard, Angel Investor

Matthew Stannard advises at the intersection of life science and data technology while co-creating and co-managing a corporate venture fund. He previously led business and corporate development for an Amsterdam-based digital health technology startup recognized for its game-changing innovations. With more than twenty years of multinational experience, he brings deep expertise in drug and medical device development, spanning discovery, clinical advancement, and patient access. Stannard is also an active angel investor, board member, and member of the investment screening committee for a Connecticut-based angel group. His portfolio includes Stratagen Bio, TETmedical, SedMed, Nuvio, DeepLook Medical, AtlasXomics, Biorez, and CoRISMA MCS Systems.